247 related articles for article (PubMed ID: 36329529)
1. A photodynamically sensitized dendritic cell vaccine that promotes the anti-tumor effects of anti-PD-L1 monoclonal antibody in a murine model of head and neck squamous cell carcinoma.
Li S; Wang D; Cheng J; Sun J; Kalvakolanu DV; Zhao X; Wang D; You Y; Zhang L; Yu D
J Transl Med; 2022 Nov; 20(1):505. PubMed ID: 36329529
[TBL] [Abstract][Full Text] [Related]
2. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner.
Mao L; Zhou JJ; Xiao Y; Yang QC; Yang SC; Wang S; Wu ZZ; Xiong HG; Yu HJ; Sun ZJ
Br J Cancer; 2023 Jun; 128(11):2126-2139. PubMed ID: 36977825
[TBL] [Abstract][Full Text] [Related]
4. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
5. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
6. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
9. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
11. Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC.
Luo X; Chen Y; Tang H; Wang H; Jiang E; Shao Z; Liu K; Zhou X; Shang Z
Cancer Sci; 2022 Jul; 113(7):2232-2245. PubMed ID: 35298069
[TBL] [Abstract][Full Text] [Related]
12. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
13. Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors.
Leddon JL; Chirra M; Frankart AJ; Agrawal A; Roof L; Trotier D; Shaikh H; Stone T; Jandarov R; Takiar V; Wise-Draper TM
Laryngoscope; 2021 Jul; 131(7):E2413-E2419. PubMed ID: 33609046
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
15. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
16. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
17. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumour cell PD-L1 test for head and neck cancers.
Kulasinghe A; Kenny L; Punyadeera C
Oral Oncol; 2017 Dec; 75():6-7. PubMed ID: 29224824
[TBL] [Abstract][Full Text] [Related]
19. Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma.
Ji J; Fan Z; Zhou F; Wang X; Shi L; Zhang H; Wang P; Yang D; Zhang L; Chen WR; Wang X
Oncotarget; 2015 Jul; 6(19):17135-46. PubMed ID: 25915530
[TBL] [Abstract][Full Text] [Related]
20. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]